346 related articles for article (PubMed ID: 9286142)
21. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
23. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
24. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
25. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
Michiels JJ
Hematology; 2005; 10 Suppl 1():215-23. PubMed ID: 16188676
[TBL] [Abstract][Full Text] [Related]
26. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
27. The histopathology of chronic myeloproliferative diseases.
Georgii A; Buesche G; Kreft A
Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
Sangle N; Cook J; Perkins S; Teman CJ; Bahler D; Hickman K; Wilson A; Prchal J; Salama ME
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
[TBL] [Abstract][Full Text] [Related]
29. Morphology of myeloproliferative neoplasms.
Ng ZY; Fuller KA; Mazza-Parton A; Erber WN
Int J Lab Hematol; 2023 Jun; 45 Suppl 2():59-70. PubMed ID: 37211431
[TBL] [Abstract][Full Text] [Related]
30. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
31. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
32. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
33. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
34. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
35. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
36. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
Marcinek J; Plank L; Szépe P; Balhárek T
Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
[TBL] [Abstract][Full Text] [Related]
37. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
[TBL] [Abstract][Full Text] [Related]
38. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities.
Kaloutsi V; Fritsch RS; Buhr T; Restrepo-Specht I; Widjaja W; Georgii A
Virchows Arch A Pathol Anat Histopathol; 1991; 418(6):493-7. PubMed ID: 2058083
[TBL] [Abstract][Full Text] [Related]
39. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
Buhr T; Georgii A; Choritz H
Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
[TBL] [Abstract][Full Text] [Related]
40. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
